文献速递中医内科中药与中成药合理使用

疏利分消方治疗难治性特发性膜性肾病肾病综合征

Herbal Medicine "Shulifenxiao" Formula for Nephrotic Syndrome of Refractory Idiopathic Membranous Nephropathy.
PubMed 文献 · Front Pharmacol · 2021-05-10

本研究回顾性分析31例对糖皮质激素或免疫抑制剂抵抗的难治性特发性膜性肾病患者,评估疏利分消方(最短治疗12个月,11例延长至24个月)的疗效。12个月时25/31例(80.7%)达缓解,24个月时10/11例(90.9%)达缓解,蛋白尿显著下降、血清白蛋白与eGFR改善,仅2例复发。

要点

  • 疏利分消方可使对激素/免疫抑制剂抵抗的RIMN患者12个月缓解率达80.7%。
  • 治疗12个月蛋白尿由6.02 g/d降至0.98 g/d,血清白蛋白由28 g/L升至37.2 g/L。
  • 随访期间仅2例复发,提示安全性较好,但仍需进一步研究验证。

核心结论

  • 疏利分消方作为临床联合疗法,可作为激素和免疫抑制剂抵抗的难治性特发性膜性肾病患者的替代治疗选择,安全性较好,但仍需进一步研究。

研究设计与样本

  • 回顾性分析31例对糖皮质激素或免疫抑制剂抵抗的成人难治性特发性膜性肾病患者;疏利分消方治疗最短12个月,11例延长至24个月;平均随访21 ± 9.16个月。

主要发现

  • 12个月时25/31例(80.7%)达缓解,其中完全缓解29.0%、部分缓解51.6%。
  • 24个月时10/11例(90.9%)达缓解,其中完全缓解54.6%、部分缓解36.4%。
  • 蛋白尿从基线6.02 g/d降至12个月0.98 g/d(p < 0.001)、24个月0.27 g/d(p = 0.003)。
  • 血清白蛋白从28 g/L升至12个月37.2 g/L(p < 0.001)、24个月41.3 g/L(p = 0.003)。
  • eGFR从100.25 ml/min/1.73 m2升至6个月118.39 ml/min/1.73 m2(p < 0.001),24个月为111.62 ml/min/1.73 m2(p = 0.008);仅2例后续复发。

关键数值与推荐

  • 主要结局为完全缓解和部分缓解,次要结局为血清肌酐和eGFR,于6、12、18、24个月测量。
  • 12个月缓解率80.7%(完全缓解29.0%、部分缓解51.6%),24个月缓解率90.9%(完全缓解54.6%、部分缓解36.4%)。

临床怎么用

  • 对常规免疫抑制方案抵抗的难治性特发性膜性肾病患者,可考虑在评估后试用疏利分消方并长期随访蛋白尿、白蛋白与eGFR。

局限性

  • 本研究为回顾性分析,样本量31例,部分患者随访至24个月仅11例,结论需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Treatment for adult patients with refractory idiopathic membranous nephropathy (RIMN) by conventional immunosuppressive regimens is not satisfactory. This study aims to evaluate the effectiveness of Chinese herbal medicine, Shulifenxiao formula, as a promising regimen. Methods: A total of 31 RIMN patients resistant to corticosteroid or immunosuppressive agents were retrospectively analyzed. Shulifenxiao treatment lasted a minimum of 12°months in all patients and extended to 24°months in 11 patients. The primary outcomes [the complete remission (CR) and partial remission (PR)] and secondary outcomes (the serum creatinine and estimated glomerular filtration rate (eGFR) levels) were measured at 6, 12, 18, and 24°months. Results: The data provided an average follow-up of 21 ± 9.16°months from baseline. The remission was attained in 25/31 patients (80.7%: CR 29.0% and PR 51.6%) at 12°months and in 10/11 patients (90.9%: CR 54.6% and PR 36.4%) at 24°months, respectively. Proteinuria reduced from 6.02 g/d at baseline to 0.98 g/d at 12°months (p < 0.001) and to 0.27 g/d at 24°months (p = 0.003); serum albumin increased from 28 g/L to 37.2 g/L at 12°months (p < 0.001) and to 41.3 g/L at 24°months (p = 0.003); eGFR improved from 100.25 ml/min/1.73 m2 to 118.39 ml/min/1.73 m2 at 6°months (p < 0.001) and finally to 111.62 ml/min/1.73 m2at 24°months (p = 0.008). Only two patients developed subsequent relapse. Conclusion: Shulifenxiao formula as a clinical cocktail therapy serves as an alternative therapeutic option for steroid and immunosuppressant-resistant RIMN patients, with a favourable safety profile, though further studies are warranted. Clinical Trial registration: http://www.chictr.org.cn, Chinese Clinical Trials Registry [ChiCTR1800019351].

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Cui H, Fu FQ, Liu B, et al. Herbal Medicine "Shulifenxiao" Formula for Nephrotic Syndrome of Refractory Idiopathic Membranous Nephropathy. Front Pharmacol. 2021. PMID: 34040535. doi:10.3389/fphar.2021.675406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。